SCHEMBL10285651

SCHEMBL10285651

CC1(C)C[C@H](CNc2cnc(Cl)c(-c3cc(NC(=O)[C@H]4CNCCO4)ncc3Cl)n2)CCO1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 12/20 0.62
CDK9 P50750 11/20 0.62
CCNK O75909 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946333 0.93 CCNT1 (0.58) CCNT1CDK9
SCHEMBL1462646 0.93 CCNT1 (0.58) CCNT1CDK9
SCHEMBL1946308 0.93 CCNT1 (0.58) CCNT1CDK9
SCHEMBL10285649 0.90 CCNT1 (0.58) CCNT1CDK9CCNK
SCHEMBL10285645 0.89 CCNT1 (0.77) CCNT1CDK9CCNK
SCHEMBL10285402 0.89 CCNT1 (0.77) CCNT1CDK9CCNK
SCHEMBL1947646 0.88 CDK9 (0.80) CCNT1CDK9
SCHEMBL1947663 0.87 CCNT1 (0.57) CCNT1CDK9
SCHEMBL1461784 0.87 CCNT1 (0.57) CCNT1CDK9
SCHEMBL1462743 0.87 CCNT1 (0.57) CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165306-A1 PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165306-A1 PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES CDK4, CDK1, CCNI CCNT1 39/4885CDK9 16/4885CCNK 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.